Compatibility of PiC Insupen Needles with a Broad Range of Pens for the Injection of Subcutaneously Administered Drugs for Diabetes

Antonio Nicolucci 1, Luca Leonardi 2

1 Center for Outcomes Research and Clinical Epidemiology (CORESEARCH Srl), Pescara (PE), Italy; 2 Pikdare S.p.A., Casnate Con Bernate (CO), Italy

Correspondence: Antonio Nicolucci, Center for Outcomes Research and Clinical Epidemiology (CORESEARCH Srl), Corso Umberto I, Pescara (PE), 103 – 65122, Italy, Tel +39 085 9047114, Fax +39 085 9047113, Email nicolucci@coresearch.it

Purpose: To test the compatibility of PiC Insupen needles with a broad range of pens produced by different manufacturers for the injection of subcutaneously administered drugs.

Patients and Methods: The “extreme” products in PiC pen needles range were considered (G33x4 mm and G29x12 mm), to verify that the compatibility was not affected by the cannula diameter and length. Following the launch of the G34x3.5mm needle, additional tests were performed comparing G33x4 and G34x3.5 pen needles. A test medium with viscosity similar to insulin was used. Additional tests were performed with a liquid with a much higher viscosity. All the requirements of the technical standard ISO 11608-2 were satisfied, and the differences between G29, G33 and G34 were negligible. Therefore, the PiC Insupen needle G33x4mm was chosen as representative of the PiC pen needles. Dose accuracy and needle hub torque were assessed, according to the ISO 11608-2:2012 norms. For pens with variable volume, two different volumes were tested (Vlow and Vhigh) in random order, testing 60 needles with Vlow and 60 with Vhigh.

Results: Overall, 50 different pens were tested. Dose accuracy acceptance criteria were met for all the pens tested, with the only exception of Vhigh for Berlipen Precision pen. The removal torque was adequate for all pens, with the only exception of Berlipen 301 and Berlipen 302 pens.

Conclusion: We documented that Pikdare needles are compatible with a large array of different pens for the injection of insulin and other drugs administered subcutaneously.

Keywords: diabetes mellitus, injection therapy, pen needle, needle compatibility

Introduction

Insulin therapy represents the cornerstone of therapy for type 1 diabetes and an important therapeutic option for patients with type 2 diabetes who are not achieving glycemic goals. 1 However, subcutaneous injections can be associated with pain, discomfort, and anxiety, 2-3 which can represent an important barrier to insulin use.

Nowadays, insulin injection pens are preferred over vials and syringes, and are designed to facilitate use, improve adherence, and provide accurate insulin delivery. To reduce the level of anxiety and discomfort associated with injections, and to improve treatment compliance in diabetes patients, new technologies have been applied for the development of thinner, shorter and tapered needles which can cause less pain and less skin trauma. 4-9 Furthermore, thin-wall technology allowed an increase in the internal diameter of the needle, producing a substantial reduction in flow resistance compared with standard needles of the same gauge. 10 These aspects are crucial, since insulin injection directly impacts on glycemic control, patient adherence, and quality of life. 11

In recent years, the introduction on the market of GLP1 receptor agonists (GLP1-RAs) and amylin analogues extended the use of treatments administered subcutaneously in type 2 diabetes beyond insulin, thus making injection aspects even more relevant.
Nowadays, a large number of reusable and prefilled injection pens is available; to provide reassurance and convenience to patients, it is important that injection pen needles fit and function correctly with the largest possible number of pens. This is a key aspect for patient trust and confidence, which can have an impact on treatment adherence.

Due to the large number of pen systems in circulation and the high frequency of launching new products with different characteristics, safety reasons require that the patient is always informed about the compatibility between the prescribed injection pen and the recommended needle.

For these reasons, the technical standard ISO 11608-2:2012 requires to declare on the packaging the list of pens with which the needle is compatible. To this purpose, the standard also requires the legal manufacturer of the needle to physically verify the compatibility between pen needles and pens with which compatibility is declared, by carrying out the test as specified by the standard. The test of compatibility entails two different aspects: the mechanical compatibility of the needle with the pen, and the dispensation of the correct fluid dose. This verification needs from the pen needle manufacturer to involve effort and resources to be performed but it's mandatory to declare the compatibility between a needle and a pen: in this way, the patient (or the caregiver) can be sure to use a needle which is fully compatible with the injection pen device and this guarantees the proper drug delivery by the needle and pen combination.

Aim of this study was to test the compatibility of the entire range of PiC Insupen needles with a broad range of pens produced by different manufacturers for the injection of subcutaneously administered drugs (especially insulin and other lower injection medicines).

Materials and Methods

As a first step, the “extreme” products in PiC pen needles range were considered, in order to verify that the compatibility was not affected by the cannula diameter and length. Therefore, the following pen needles were considered: G33x4 mm (the shortest and thinnest), and G29x12 mm (the longest and thickest). Furthermore, to reduce the variability of results due to external factors, the same injection system (Humapen Luxura from Eli Lilly, a reusable pen) was used to test both pen needle types, and a test medium instead of insulin was used (viscosity = 1 cP, similar to insulin viscosity; density = 1 g/mL).

Results show that all the requirements of the technical standard ISO 11608-2 were satisfied with both pen needles types (Supplementary Table 1), and that the differences between G29 and G33 were negligible.

Additional tests were performed to verify that a liquid with a much higher viscosity than insulin does not affect the dose accuracy; to this purpose, a test liquid with a viscosity of 10 cP (glycerol solution, density: 1,17,423 g/mL) was used. G33 was chosen as the test needle, since it is thinner, so the probability of cannula occlusion could be higher than with G29. Results show that all the requirements of the technical standard ISO 11608-2 were satisfied also with the high viscosity medium (Supplementary Table 2), and that the differences between G29 and G33 were negligible.

Following the launch of the G34x3.5mm needle, additional tests were performed to verify that the compatibility test produced the same results when tested on G33x4 and G34x3.5 pen needles, as already demonstrated in the comparison between G33x4 and G29x12. The Solostar system with Lantus Glargine insulin was used. Even in this case, all the requirements of the technical standard ISO 11608–2 were satisfied with both pen needles types (Supplementary Table 3); the differences between G34 and G33 were negligible.

Therefore, the PiC Insupen needle G33x4mm was chosen as representative of the PiC pen needles.

Dose accuracy and needle hub torque were assessed. Overall, 50 different pens were tested.

Needles were tested according to the norms dictated by the ISO 11608-2:2012, Needle-based injection systems for medical use, Requirements and test methods — Part 2: Needles. Each compatibility test consisted in mounting the needles onto the pens, verifying that the selected dose was properly ejected by the pen plus needle system and checking that the unscrewing torque to remove the needle from the pen was adequate. The devices were placed in the testing area under standard atmospheric conditions (18–25°C; 25–75% relative humidity) for a minimum of 4 hours to ensure acclimatization.

The number of needles tested for each needle type and the number of pens tested for each pen type was in line with the requirements of the ISO norm and calculated according to the specific pen’s characteristics.
For pens with variable volume, two different volumes were tested (Vlow and Vhigh) in random order, testing 60 needles with Vlow and 60 with Vhigh. The volumes were calculated as follows:

- Vlow ≤ 10% of injection system (NIS) maximum dosage.
- Vhigh ≥ 90% of NIS maximum dosage.

For example, if the NIS maximum dosage was 60 IU, then Vlow ≤ 10% of 60 IU = 6 IU.
- Vhigh ≥ 90% of 60 IU = 54 IU.

For NIS with fixed dosage, only 60 pen needles were tested, ejecting the fixed volume.

For some disposable NIS, prefilled with drugs different from insulin, not only one fixed dose but a limited number of prespecified doses is available. In this case, Vlow and Vhigh have been established to reflect the minimum and maximum injectable dose. As an example, the Victoza pen from Novo Nordisk can deliver three different doses of the GLP-1 RA liraglutide: 0.6 mg, 1.2 mg, and 1.8 mg. Therefore, Vlow was fixed at the volume correspondent to 0.6 mg and Vmax at the volume correspondent to 1.8 mg.

So, 120 needles were tested with each variable dose pen and 60 with each fixed dose pen.

For reusable pens, one device was used and only the cartridges were changed.

Before starting the validation, the priming was done. For prefilled pens, a spare needle was assembled and 2 units of test medium were injected, in order to be sure that the piston of the NIS was in contact with the plunger of the vial and to purge air bubbles from the cartridge. For reusable pens, the first cartridge was inserted into the injection system, a spare needle was assembled and, as for prefilled pens, 2 units of test medium were injected, in order to be sure that the piston of the NIS was in contact with the plunger of the vial and to purge air bubbles from the cartridge.

The validation involved the following steps.

- The needle was screwed on the pen with a torque of 0.07 ± 0.01 Nm. After at least 10 seconds, the target dose was set on the pen and the volume to be verified was expelled.
- The liquid was dispensed directly on the scale, in a 10 mL flask, previously filled with a small amount of test medium and calibrated, waiting 5 seconds after the injection; then the liquid was weighted within 5 seconds after stabilization of the scale. Without moving the flask, the scale was recalibrated to be ready for the next injection. The needle was unscrewed. Steps were repeated, testing 60 different needles with Vlow and 60 with Vhigh (total 120 needles), according to a random or alternating dosing sequence, changing the cartridge (or the pen) when necessary and performing the priming again every time. The volume was calculated dividing the mass by the density of the liquid under test.

For NIS with fixed dosage, only 60 pen needles were tested, ejecting the fixed volume.

### Statistical Methods

The needle type and pen type were judged as having passed the compatibility test if:

\[
S + (k \times Sd) \leq UL
\]

and

\[
S - (k \times Sd) \geq LL
\]

where:
- \( S \) is sample mean,
- \( Sd \) is sample standard deviation,
- \( UL \) is upper specification limit,
- \( LL \) is the lower specification limit,
- \( k \) is the coverage factor (n=60, k=2.67 assuming a confidence interval of 95% and a reliability of 97.5%).

For doses ≤ 0.20 mL, the dose accuracy test was considered acceptable if the calculated values (of the collected dispensed fluid doses) were within ±0.01 mL of the targeted dose (Vlow or Vhigh).

For doses > 0.20 mL, the dose accuracy test was considered acceptable if the calculated values (of the collected dispensed fluid doses) are within ±5% of the targeted dose (Vlow or Vhigh).
| Pen                      | S     | S_{rd} | UL | LL | S_+(k*S_{sd}) & S_-(k*S_{sd}) | S_+(k*S_{sd}) & S_-(k*S_{sd}) |
|--------------------------|-------|--------|----|----|--------------------------------|--------------------------------|
| Byetta 5 µg              | 0.0608| 0.0016 | 0.070 | 0.050 | 0.0650 & 0.0566 | Yes & Yes |
| Byetta 10 µg             | 0.0397| 0.0012 | 0.0500 | 0.0300 | 0.0429 & 0.0365 | Yes & Yes |
| Victoza 6 mg/mL          | 0.0965| 0.0022 | 0.1100 | 0.0900 | 0.1023 & 0.0906 | Yes & Yes |
| HumaPen Luxura HD        | 0.0307| 0.0007 | 0.0400 | 0.0200 | 0.0326 & 0.0288 | Yes & Yes |
| HumaPen Savio            | 0.0608| 0.0016 | 0.070 | 0.050 | 0.0650 & 0.0566 | Yes & Yes |
| HumaPen Luxura           | 0.0613| 0.0021 | 0.070 | 0.050 | 0.067 & 0.056 | Yes & Yes |
| HumaPen Memoir           | 0.061 | 0.0010 | 0.070 | 0.050 | 0.064 & 0.058 | Yes & Yes |
| FlexPen                  | 0.059 | 0.0012 | 0.070 | 0.050 | 0.062 & 0.056 | Yes & Yes |
| NovoPen Echo             | 0.031 | 0.0012 | 0.040 | 0.020 | 0.034 & 0.028 | Yes & Yes |
| KwikPen                  | 0.061 | 0.0013 | 0.070 | 0.050 | 0.064 & 0.057 | Yes & Yes |
| Innolet                  | 0.050 | 0.0013 | 0.060 | 0.040 | 0.053 & 0.047 | Yes & Yes |
| NovoPen 3                | 0.070 | 0.0013 | 0.080 | 0.060 | 0.073 & 0.066 | Yes & Yes |
| NovoPen 4                | 0.061 | 0.0019 | 0.070 | 0.050 | 0.067 & 0.056 | Yes & Yes |
| Lymnumia 10 µg           | Not applicable | | | | | |
| ClikStar                 | 0.083 | 0.0022 | 0.090 | 0.070 | 0.089 & 0.077 | Yes & Yes |
| SoloStar                 | 0.080 | 0.0015 | 0.090 | 0.070 | 0.084 & 0.076 | Yes & Yes |
| Toujeo Solostar          | 0.01711 | 0.00067 | 0.02666 | 0.00666 | 0.01890 & 0.01532 | Yes & Yes |
| JuniorStar               | 0.031 | 0.0013 | 0.040 | 0.020 | 0.034 & 0.028 | Yes & Yes |
| NovoPen Junior           | 0.036 | 0.0016 | 0.045 | 0.025 | 0.040 & 0.032 | Yes & Yes |
| Ypsopen                  | 0.060 | 0.0016 | 0.070 | 0.050 | 0.064 & 0.055 | Yes & Yes |
| Autopen Classic 1–21 IU  | 0.020 | 0.0008 | 0.030 | 0.010 | 0.022 & 0.018 | Yes & Yes |
| Autopen Classic 2–42 IU  | 0.039 | 0.0010 | 0.050 | 0.030 | 0.042 & 0.036 | Yes & Yes |
| Autopen 24 1–21 IU       | 0.020 | 0.0009 | 0.030 | 0.010 | 0.022 & 0.017 | Yes & Yes |
| Autopen 24 2–42 IU       | 0.039 | 0.0020 | 0.050 | 0.030 | 0.044 & 0.033 | Yes & Yes |

Table 1: Dose Accuracy results (as per ISO 11608–2 11.5.2)
| Drug                        | Torque (Nm) | Removal Torque (N) | Removal Torque (N) | Removal Torque (N) | Removal Torque (N) | Removal Torque (N) | Y/N |
|-----------------------------|-------------|--------------------|--------------------|--------------------|--------------------|--------------------|-----|
| Gensupen                   | 0.038       | 0.0013             | 0.050              | 0.030              | 0.042              | 0.035              | Yes |
| Flextouch                  | 0.080       | 0.0014             | 0.090              | 0.070              | 0.084              | 0.076              | Yes |
| Berlipen Aera2             | 0.064       | 0.0023             | 0.070              | 0.050              | 0.070              | 0.058              | Yes |
| Berlipen 301*              | 0.019       | 0.0013             | 0.030              | 0.010              | 0.023              | 0.016              | Yes |
| Berlipen 302*              | 0.036       | 0.0022             | 0.050              | 0.030              | 0.042              | 0.030              | Yes |
| Berlipen Precision         | 0.027       | 0.0030             | 0.035              | 0.015              | 0.035              | 0.019              | Yes |
| Forsteo                    | 0.081       | 0.0015             | 0.090              | 0.070              | 0.085              | 0.077              | Yes |
| NovoPen5                   | 0.062       | 0.0025             | 0.070              | 0.050              | 0.069              | 0.055              | Yes |
| Soliqua/Suliqua (40 IU)    | 0.021       | 0.0010             | 0.050              | 0.030              | 0.044              | 0.039              | Yes |
| Soliqua/Suliqua (60 IU)    | 0.026       | 0.0013             | 0.070              | 0.050              | 0.066              | 0.059              | Yes |
| Humalog Li-200 Kwikpen     | 0.030       | 0.0007             | 0.041              | 0.021              | 0.033              | 0.029              | Yes |
| Gensupen Improve           | 0.037       | 0.0012             | 0.047              | 0.027              | 0.040              | 0.034              | Yes |
| Wangbangpen                | 0.044       | 0.0009             | 0.054              | 0.034              | 0.047              | 0.042              | Yes |
| Gansulin Pen               | 0.059       | 0.0006             | 0.069              | 0.049              | 0.061              | 0.058              | Yes |
| Sanofi Toujeo Max SoloStar | 0.054       | 0.0008             | 0.064              | 0.044              | 0.056              | 0.052              | Yes |
| Humulin KwikPen 70–30      | 0.061       | 0.0005             | 0.070              | 0.050              | 0.062              | 0.059              | Yes |
| SymlinPen 60–120           | 0.061       | 0.0004             | 0.070              | 0.050              | 0.062              | 0.060              | Yes |
| SymlinPen 15–60            | 0.015       | 0.0004             | 0.025              | 0.005              | 0.016              | 0.014              | Yes |
| Gensupen2                  | 0.056       | 0.0017             | 0.070              | 0.050              | 0.061              | 0.052              | Yes |
| Semgleè                   | 0.079       | 0.0020             | 0.090              | 0.070              | 0.084              | 0.073              | Yes |
| Aciste                     | 0.028       | 0.0017             | 0.040              | 0.020              | 0.033              | 0.024              | Yes |

*Note: *An assembly torque of 0.07 ± 0.01 Nm was always applied to assembled needles on pens; after that, the removal torque detected was ≤0.100 Nm for all pens, with the only exception of Berlipen 301 and Berlipen 302.
As an example, if $V_{\text{low}}$ is 0.06 mL and $V_{\text{high}}$ is 0.54 mL, the acceptance criteria will be $LL=0.05$ and $UL=0.07$ for $V_{\text{low}}$ and $LL=0.513$ and $UL=0.567$ for $V_{\text{high}}$.

The same needles used for the dose accuracy testing were used for the needle hub removal torque testing. For removal torque, a value of 0.100 Nm or less was deemed adequate.

Statistical analyses were performed using the SPSS software ver. 23.0 (IBM, Armonk, NY, USA).

**Results**

The list of the 50 pens tested along with dose accuracy parameters are reported in Table 1. Dose accuracy acceptance criteria were met for all insulin and GLP-1 RA pens tested, with the only exception of $V_{\text{high}}$ for Berlipen Precision pen $[S+(k*S_{sd})=0.243; UL=0.236]$. After assembling needles on pens with the required torque value, the removal torque was $\leq 0.100$ Nm, and therefore compliant for all the pens, except for Berlipen 301 and Berlipen 302 pens (in these cases the removal torque exceeded 0.100 Nm).

**Discussion**

The compatibility of needles with any brand of pens represents an important aspect of injective therapies, particularly in the case of complex schemes, such as an insulin basal-bolus regimen, or the combination of insulin therapy with a GLP1-RA. Furthermore, it avoids the need of changing the kind of needle used each time the treatment or brand of drug is changed. The possibility to use the same needle for different kinds of pens increases the confidence of the patient, at it is likely to reduce the anxiety associated with the injection.

These aspects are crucial, since insulin injection directly impacts on glycemic control, patient adherence, and quality of life. For these reasons, the technical standard ISO 11608-2: 2012 requires to declare on the packaging the list of pens with which the needle is compatible. The test of compatibility entails two different aspects: the mechanical compatibility of the needle with the pen, and the dispensation of the correct fluid dose. However, there is scant published information on the compatibility of injection pen needles with different injection pens. To our knowledge, only one study tested two types of pen needles with a range of injection pens for diabetes medication. The study considered two 30G 8mm needles (NovoFine and NovoFine Autocover) to assess their compatibility with 21 different pens. The needles were tested by attaching them according to ISO 11608-2 and verifying penetration into the cartridge using air shots and two-dimensional X-rays. Needles were compatible with most of the injection pen types from other manufacturers in terms of correct attachment and detachment to the pen thread. Penetration was present in all cases where the needles could be mounted onto a pen. Dose accuracy was not evaluated in this study. No additional studies on the compatibility and dose accuracy of thinner and shorter needles are available. The lack of studies underlines the need for more extensive, formal tests of compatibility of pen needles.

**Conclusion**

We documented that Pikdare needles are compatible with a large array of different pens for the injection of insulin and other drugs administered subcutaneously. The amount of test fluid injected was always within the range recommended by the ISO standards, with only one exception, irrespective of the viscosity of the fluid and the size of the needle; the mechanical fitting of needle hub on the different pen types was also adequate.

**Disclosure**

Luca Leonardi is Pikdare S.p.A. employee. Antonio Nicolucci has received honoraria from AstraZeneca, Eli Lilly, Novo Nordisk, and research support from Alfasigma, Medtronic, Novo Nordisk, Pikdare, Sanofi, Shionogi, SOBI. The authors report no other conflicts of interest in this work.

**References**

1. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110. doi:10.2337/dc20-S009
2. Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Pract Diabetes Int. 1997;14:95–99. doi:10.1002/pdi.1960140404

3. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239–246. doi:10.1016/S0168-8227(99)00099-6

4. Korytkowski M, Bell D, Jacobsen C, et al. A multiCenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836–2848. doi:10.1016/S0149-2918(03)80337-5

5. Korytkowski M, Niskanen L, Asakura T, et al. Addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(Suppl B):S89–S100. doi:10.1016/j.clinthera.2005.11.019

6. Magwire ML. Addressing barriers to insulin therapy: the role of insulin pens. Am J Ther. 2011;18:392–402. doi:10.1097/MJT.0b013e3181ef4dde

7. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486–496. doi:10.1016/S0149-2918(98)80058-1

8. Grabner M, Chu J, Raparla S, et al. Clinical and economic Outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial. Postgrad Med. 2013;125:204–213. doi:10.3810/pgm.2013.05.2656

9. Molin A, Larsen C, Lawton SA. Reduced flow resistance in insulin pen needles designed with thin wall technology. Diabetes. 2002;51(Suppl 1):A475.

10. O’Neal KS, Johnson J, Swar S. Nontraditional considerations with insulin needle length selection. Diabetes Spectr. 2015;28:264–267. doi:10.2337/diaspect.28.4.264

11. Buus P, Lillevre SK, Larsen K. Compatibility testing of two types of pen needles with a range of injection pens for diabetes medication. Curr Med Res Opin. 2011;27:589–592. doi:10.1185/03007995.2010.547574